Parrini, I.; Lucà , F.; Rao, C.M.; Parise, G.; Micali, L.R.; Musumeci, G.; La Meir, M.; Colivicchi, F.; Gulizia, M.M.; Gelsomino, S.
Superiority of Direct Oral Anticoagulants over Vitamin K Antagonists in Oncological Patients with Atrial Fibrillation: Analysis of Efficacy and Safety Outcomes. J. Clin. Med. 2022, 11, 5712.
https://doi.org/10.3390/jcm11195712
AMA Style
Parrini I, Lucà F, Rao CM, Parise G, Micali LR, Musumeci G, La Meir M, Colivicchi F, Gulizia MM, Gelsomino S.
Superiority of Direct Oral Anticoagulants over Vitamin K Antagonists in Oncological Patients with Atrial Fibrillation: Analysis of Efficacy and Safety Outcomes. Journal of Clinical Medicine. 2022; 11(19):5712.
https://doi.org/10.3390/jcm11195712
Chicago/Turabian Style
Parrini, Iris, Fabiana Lucà , Carmelo Massimiliano Rao, Gianmarco Parise, Linda Renata Micali, Giuseppe Musumeci, Mark La Meir, Furio Colivicchi, Michele Massimo Gulizia, and Sandro Gelsomino.
2022. "Superiority of Direct Oral Anticoagulants over Vitamin K Antagonists in Oncological Patients with Atrial Fibrillation: Analysis of Efficacy and Safety Outcomes" Journal of Clinical Medicine 11, no. 19: 5712.
https://doi.org/10.3390/jcm11195712
APA Style
Parrini, I., Lucà , F., Rao, C. M., Parise, G., Micali, L. R., Musumeci, G., La Meir, M., Colivicchi, F., Gulizia, M. M., & Gelsomino, S.
(2022). Superiority of Direct Oral Anticoagulants over Vitamin K Antagonists in Oncological Patients with Atrial Fibrillation: Analysis of Efficacy and Safety Outcomes. Journal of Clinical Medicine, 11(19), 5712.
https://doi.org/10.3390/jcm11195712
